 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Select Presentations by BU ADC Investigators & Affiliates at the International Conference on Alzheimer’s Disease (ICAD)Dr. Carmela Abraham, “Klotho, aging and Alzheimer’s disease (AD)” Dr. Nancy Emerson Lombardo, “Feasibility of evidence-based brain healthy nutrition in clinical practice with individuals and private groups” Dr. Lindsay Farrer, “Distinct variants in SORL1 are associated with cerebrovascular and neurodegenerative changes related to AD;” and “Comparison of AD and vascular dementia patients using MRI-based measures of atrophy” Dr. Brandon Gavett, “The diagnostic utility of the NAB list learning test in the assessment of AD and mild cognitive impairment (MCI)” Dr. Lee Goldstein, “AD beta-amyloid pathology in down syndrome cataract” Dr. Robert Green, “Safety and efficacy of tarenflurbil in subjects with mild AD: Results from an 18-month multi-center Phase III trial;” “Impact of a condensed protocol for disclosing APOE genotype to first-degree relatives of people with AD;” and “The impact of an education and risk evaluation protocol on perceived benefits and risks of genetic susceptibility testing for AD” Dr. Angela Jefferson, “Systolic function is associated with brain aging: The Framingham Heart Study” Dr. Ann McKee, “Epigenetic modification in a monozygotic twin with AD” Dr. Robert Stern, “At the crossroads: Development and evaluation of a dementia caregiver group intervention to assist in driving cessation;” “Development of a new scale measuring psychological impact of genetic susceptibility testing for AD;” and “Cognitive complaints in MCI and AD” Dr. Benjamin Wolozin, “Use of angiotensin receptor blockers is associated with a lower incidence and progression of AD;” and “LRRK2 regulates the stress response in C. elegans and mammalian cells” |
|
 |
 |
 |
 |
 |
|